Study guide
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10)
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10)
Key Takeaways Explain This Topic AI
Reproductive aging is driven by primordial oocyte depletion, declining inhibin B production by granulosa cells, loss of negative feedback at the anterior pituitary, and compensatory FSH elevation alongside erratic estradiol fluctuations.
The STRAW+10 clinical staging system categorizes reproductive aging into Stage -2 (early menopausal transition: persistent cycle length difference >=7 days) and Stage -1 (late menopausal transition: amenorrhea interval >=60 days), culminating in Stage 0 (final menstrual period).
Natural menopause is diagnosed clinically after 12 consecutive months of amenorrhea in a woman aged 45 years or older without pathological cause; routine serum FSH and estradiol measurements are erratic, non-diagnostic, and not recommended.
Primary Ovarian Insufficiency (POI) is defined as hypergonadotropic hypogonadism before age 40 (FSH >25 IU/L with at least 4 months of disordered cycles; the 2024 ESHRE/ASRM guideline needs only one elevated value) and mandates genetic, karyotypic, and autoimmune screening.
Vasomotor symptoms (hot flashes and night sweats) result from estrogen-withdrawal-induced narrowing of the hypothalamic thermoregulatory set point, driven by hypertrophy and hyperactivity of KNDy (kisspeptin, neurokinin B, dynorphin) neurons acting on neurokinin 3 (NK3) receptors.
Last updated: October 2026
Endocrinologic Dynamics of Reproductive Aging
The menopausal transition is driven by progressive depletion of the finite ovarian follicular reserve. At birth, ovaries harbor approximately 1 to 2 million primordial follicles, decreasing to 300,000 to 400,000 at menarche and fewer than 1,000 at menopause. Reproductive aging is characterized by distinct, non-linear neuroendocrine shifts:
Inhibin B Decline: Produced by granulosa cells of small growing antral follicles, inhibin B is the earliest biomarker to fall as the follicular cohort contracts.
Compensatory FSH Elevation: Loss of inhibin B negative feedback on pituitary gonadotrophs unleashes a compensatory rise in follicle-stimulating hormone (FSH) , even while circulating 17-beta estradiol (E2) and luteinizing hormone (LH) remain normal.
Erratic Estradiol Fluctuations: Elevated FSH hyperstimulates remaining follicles, causing unpredictable multifollicular waves. Serum 17-beta estradiol swings widely between supraphysiologic surges (>500 pg/mL) and postmenopausal nadirs (<20 pg/mL).
Anovulation & Progesterone Deficit: Irregular follicular recruitment produces frequent anovulatory cycles and luteal phase defects. Unopposed estrogen stimulation results in irregular cycle lengths, heavy menstrual bleeding, and endometrial proliferation.
Follicular Exhaustion: When oocyte reserves fall below roughly 1,000 follicles, steroidogenesis ceases. Estrone (E1), derived from peripheral aromatization of adrenal androstenedione in adipose tissue, becomes the predominant circulating estrogen.
The STRAW+10 Clinical Staging System
The Stages of Reproductive Aging Workshop (STRAW+10) is the clinical gold standard for categorizing female reproductive aging based on bleeding patterns and endocrine markers.
Stage Phase Menstrual Criteria Endocrine Features Clinical Focus
Stage -2 Early Menopausal Transition Persistent difference of ≥7 days in consecutive cycle lengths Variable early follicular FSH; low AMH and antral follicle count Entry into perimenopause; subtle cycle irregularity recurring within 10 cycles.
Stage -1 Late Menopausal Transition Marked irregularity with ≥1 interval of amenorrhea ≥60 days Elevated FSH (>25 mIU/mL); erratic estradiol; low inhibin B Vasomotor symptoms peak in frequency and severity.
Stage 0 Final Menstrual Period (FMP) Final spontaneous menses Markedly elevated FSH; low estradiol Diagnosed retrospectively after 12 consecutive months of amenorrhea .
Stage +1 Early Postmenopause (about 5–8 years) Complete amenorrhea (+1a and +1b: 1 year each; +1c: 3–6 years) FSH and estradiol stabilize at postmenopausal nadirs Most rapid bone loss (+1a/b); VMS gradually attenuate (+1c).
Stage +2 Late Postmenopause (remaining lifespan) Complete amenorrhea Permanently high FSH; permanently low estradiol Genitourinary syndrome of menopause (GSM) and somatic aging predominate.
Important
Natural menopause is diagnosed clinically after 12 consecutive months of amenorrhea in a woman aged 45 or older without pathological etiology.
Routine measurement of serum FSH and estradiol is unreliable and NOT recommended in women over 45. Due to wide day-to-day endocrine fluctuations, a single normal FSH does not exclude perimenopause, nor does an elevated FSH prove permanent sterility.
Primary Ovarian Insufficiency (POI)
Primary Ovarian Insufficiency (POI) refers to transient or permanent loss of ovarian function before age 40. Unlike natural menopause, 5% to 10% of women with POI experience intermittent, unpredictable ovulation and spontaneous pregnancy.
Diagnostic Thresholds
Age younger than 40 years .
At least 4 months of secondary amenorrhea or oligomenorrhea .
Elevated serum FSH >25 IU/L . The 2024 ESHRE/ASRM/CRE/IMS guideline needs only one elevated value, repeated 4–6 weeks later only if the diagnosis is uncertain; AMH can help when results conflict.
Etiologic Workup
Once confirmed, clinicians must execute a comprehensive etiologic evaluation:
Genetic Testing: High-resolution karyotype (evaluating for 45,X mosaicism or structural X anomalies) and FMR1 gene premutation testing (fragile X carrier status; 55–200 CGG repeats).
Autoimmune Screening: Anti-adrenal 21-hydroxylase antibodies (evaluating for autoimmune Addison disease / polyglandular syndromes) and anti-thyroid peroxidase (anti-TPO) antibodies with TSH.
Pelvic Ultrasonography: Confirms reduced ovarian volume and absent antral follicles.
Bone Density Testing: Baseline central DEXA scan to assess early bone mineral loss from premature hypoestrogenism.
Pathophysiology of Vasomotor Symptoms (VMS)
Vasomotor symptoms (hot flashes, night sweats) affect roughly 80% of women during the menopausal transition, lasting an average of 7 to 9 years.
Hypothalamic Mechanisms & KNDy Neurons
Thermoregulation is coordinated by the preoptic anterior hypothalamus, which normally maintains core temperature within a tight thermoneutral zone (~0.4°C). Estrogen withdrawal disrupts this center via hypothalamic KNDy neurons:
Neurons in the infundibular nucleus co-express Kisspeptin, Neurokinin B (NKB), and Dynorphin (KNDy neurons) .
Circulating estrogen normally exerts tonic negative feedback on KNDy neurons.
With declining estradiol, negative inhibition is lost, causing KNDy hypertrophy and hypersecretion of neurokinin B .
Excess neurokinin B activates neurokinin 3 (NK3) receptors on thermoregulatory effector neurons in the preoptic area.
This narrows the thermoneutral zone, causing minimal increases in core or ambient temperature to trigger exaggerated heat-dissipation cascades.
Clinical Manifestations & Quality of Life
Heat Dissipation: Sympathetic activation drives rapid cutaneous vasodilation (flushing of face, neck, and chest), diaphoresis, and transient tachycardia (+10–20 bpm), followed by chills as core temperature drops.
Sleep Architecture Disruption: Nocturnal hot flashes cause recurrent cortical micro-arousals, disrupting slow-wave (stage N3) and rapid eye movement (REM) sleep.
Cognitive & Mood Sequelae: Chronic sleep fragmentation triggers daytime fatigue, impaired concentration ("brain fog"), heightened irritability, and depressive symptoms.
Note
Defining KNDy-NK3 receptor hyperactivation directly led to the development of selective NK3 receptor antagonists (such as fezolinetant), providing non-hormonal thermoregulatory control.